POTENTIAL OPTIMISATION OF TREATMENT WITH USTEKINUMAB IN CROHN'S DISEASE (submitted in 2019)
4CPS-121
EVALUATION OF COST AND EFFICACY OF ECULIZUMAB IN COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY IN THE CLINICAL SETTING (submitted in 2019)
4CPS-120
TEN YEAR ANALYSIS OF THE USE OF INFLIXIMAB IN ULCERATIVE COLITIS (submitted in 2019)
4CPS-119
“REAL WORLD” EXPERIENCE OF TOFACITINIB AND BARICITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: EFFECTIVENESS AND SAFETY EVALUATION (submitted in 2019)
4CPS-118
REAL CLINICAL IMPACT OF DRUG-DRUG INTERACTIONS OF IMMUNOSUPPRESSANTS IN TRANSPLANT PATIENTS. (submitted in 2019)
4CPS-117
CASE REPORT: USEFULNESS OF THERAPEUTIC DRUG MONITORING OF VEDOLIZUMAB IN MANAGING ACUTE GRAFT VERSUS HOST DISEASE (submitted in 2019)
4CPS-116
TEN YEARS OF EXPERTISE IN USTEKINUMAB USE FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS (submitted in 2019)
4CPS-115
THERAPEUTIC DRUG MONITORING OF ETANERCEPT BIOSIMILAR IN PSORIATIC PATIENTS (submitted in 2019)
4CPS-114
BELIEFS ABOUT MEDICATION AND QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH NATALIZUMAB (submitted in 2019)
4CPS-113
INOTUZUMAB OZOGAMIZIN FOR THE TREATMENT OF THE RELAPSE B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA IN AN ADULT PATIENT: A CASE REPORT. (submitted in 2019)
4CPS-112
ADHERENCE TO ADALIMUMAB, GOLIMUMAB AND USTEKINUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE (submitted in 2019)
4CPS-111
CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB BIOSIMILAR INFLECTRA IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHROPATHY AND ANKYLOSING SPONDYLITIS NAÏVE AND SWITCHED PATIENTS: AFTER 5 YEARS OF FOLLOW-UP (submitted in 2019)
4CPS-110
VEDOLIZUMAB: OUTCOMES AND THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE (submitted in 2019)
4CPS-109
ANALYSIS OF CHANGES IN DISEASE MODIFYING TREATMENT IN THE MANAGEMENT OF PATIENTS WITH MULTIPLE SCLEROSIS (submitted in 2019)
4CPS-108
A REVIEW OF INFLIXIMAB BIOSIMILAR TO BIOSIMILAR SWITCH: REMSIMA TO FLIXABI (submitted in 2019)
